The European bladder cancer market is estimated to grow modestly, at a CAGR of around 9.3%, during the forecast period. The growth of the market is attributed to well-developed healthcare infrastructure coupled with significant healthcare expenditure and growing prevalence and incidence of bladder cancer across many European economies. Moreover, the high prevalence of cancer and high awareness of cancer in the region is contributing to market growth. Sedentary lifestyles such as smoking, consumption of drugs, and alcohol in the country are the major factors for the growing incidence of bladder cancer among men and women. Government initiatives, programs, and funding for cancer-related programs are also contributing to the growth of the bladder cancer market in the region. Among countries analyzed in the European bladder cancer market, RoE holds a significant share due to the incidence rate of bladder cancer in Denmark, Netherlands, Sweden, and Belgium.
A full report of European Bladder Cancer Market is available at: https://www.omrglobal.com/industry-reports/european-bladder-cancer-market
The European bladder cancer market is segmented into cancer type, diagnosis, and treatment. Based on cancer type, the market is segmented into transitional cell bladder cancer/ urothelial carcinoma, squamous cell bladder cancer, adenocarcinoma, and other rare types (sarcomas, carcinoma in situ). Based on the diagnosis, the market is segmented into cystoscopy, biopsy, urinalysis, urine cytology, intravenous pyelogram (IVP), and others. Based on treatment, the market is segmented into chemotherapy, immunotherapy, radiation therapy, surgery, and other treatment which include targeted therapy. The chemotherapy is highly adopted as it kills cancer cells that are spread to other parts of the body, far from its primary tumor.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/european-bladder-cancer-market
The companies which are contributing to the growth of the European bladder cancer market include AstraZeneca PLC, Bristol-Myers Squibb, Co., Eli Lilly & Co., GlaxoSmithKline PLC, and Pfizer, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.
European Bladder Cancer Market- Segmentation
By Cancer type
- Transitional Cell Bladder Cancer/ Urothelial Carcinoma
- Squamous Cell Bladder Cancer
- Adenocarcinoma
- Other Rare Types (Sarcomas, Carcinoma in Situ)
By Diagnosis Method
- Cystoscopy
- Biopsy
- Urinalysis
- Urine Cytology
- Intravenous Pyelogram (Ivp)
- Other
By Therapy
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Surgery
- Other
